136 related articles for article (PubMed ID: 10242286)
1. Informing patients about drugs: a wrong way and a right way.
Woodson DW
Med World News; 1979 Jun; 20(13):6. PubMed ID: 10242286
[No Abstract] [Full Text] [Related]
2. Fourteen fallacies about patient package inserts.
Goyan J
West J Med; 1981 May; 134(5):463-8. PubMed ID: 7257361
[No Abstract] [Full Text] [Related]
3. Regulating off-label drug use--rethinking the role of the FDA.
Stafford RS
N Engl J Med; 2008 Apr; 358(14):1427-9. PubMed ID: 18385495
[No Abstract] [Full Text] [Related]
4. Developing drug information for patients.
Hecht A
FDA Consum; 1977 Sep; 11(7):16-9. PubMed ID: 10304999
[No Abstract] [Full Text] [Related]
5. Rx with a dose of info.
Miller RW
FDA Consum; 1980 Nov; 14(9):22-3. PubMed ID: 10309292
[TBL] [Abstract][Full Text] [Related]
6. Prescription drug products; patient labeling requirements: proposed rule.
Fed Regist; 1979 Jul; 44(131 Pt 2):40015-41. PubMed ID: 10242793
[No Abstract] [Full Text] [Related]
7. Did FDA jump the gun?
Archambault GF
Hosp Formul; 1977 Oct; 12(10):722. PubMed ID: 10305387
[No Abstract] [Full Text] [Related]
8. Will PPIs affect your patients' attitudes?
Patient Care; 1979 Feb; 13(3):190-1, 195-6. PubMed ID: 10240261
[No Abstract] [Full Text] [Related]
9. Off-label or off-limits?
Ratner M; Gura T
Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
[No Abstract] [Full Text] [Related]
10. The status of unit-of-use in Europe and the United States: an evolution in drug dispensing.
Archambault GF
Hosp Formul; 1979 Jan; 14(1):70-1, 75-6, 78-9. PubMed ID: 10297341
[No Abstract] [Full Text] [Related]
11. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
Dorfman HL; Quinn VM; Brophy EA
Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
[No Abstract] [Full Text] [Related]
12. Educating patients about their medications: the potential and limitations of written drug information.
Shrank WH; Avorn J
Health Aff (Millwood); 2007; 26(3):731-40. PubMed ID: 17485751
[TBL] [Abstract][Full Text] [Related]
13. Progestational drug products for human use; requirements for labeling directed to the patient. Food and Drug Administration, HHS. Final rule.
Fed Regist; 1999 Nov; 64(220):62110-2. PubMed ID: 11010691
[TBL] [Abstract][Full Text] [Related]
14. The case for preemption of prescription drug failure-to-warn claims.
Kim CH
Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
[No Abstract] [Full Text] [Related]
15. Patient package inserts: the proper prescription?
Rowe HM
Food Drug Law J; 1995; 50(1):95-124. PubMed ID: 10342988
[No Abstract] [Full Text] [Related]
16. Informing women about 'The Pill'.
FDA Consum; 1977 Feb; 11(1):20-1. PubMed ID: 10304983
[No Abstract] [Full Text] [Related]
17. Informing patients on prescription drugs.
Hecht A
FDA Consum; 1976 Mar; 10(2):4-7. PubMed ID: 828894
[No Abstract] [Full Text] [Related]
18. Importing prescription drugs: risky business.
Hassel L; Arzuaga P
Empl Benefits J; 2003 Dec; 28(4):83-6. PubMed ID: 14712740
[TBL] [Abstract][Full Text] [Related]
19. The right of privacy in choosing medical treatment: should terminally ill persons have access to drugs not yet approved by the Food and Drug Administration?
Power SH
John Marshall Law Rev; 1987; 20(4):693-714. PubMed ID: 11650094
[No Abstract] [Full Text] [Related]
20. Off-label pharmaceutical use: balancing information, risks, and benefits.
Kozma CM
Manag Care Interface; 2004 Jan; 17(1):29-30. PubMed ID: 15035597
[No Abstract] [Full Text] [Related]
[Next] [New Search]
